» Articles » PMID: 37993892

A Comprehensive Model for Assessing and Classifying Patients with Thrombotic Microangiopathy: the TMA-INSIGHT Score

Abstract

Background: Thrombotic Microangiopathy (TMA) is a syndrome characterized by the presence of anemia, thrombocytopenia and organ damage and has multiple etiologies. The primary aim is to develop an algorithm to classify TMA (TMA-INSIGHT score).

Methods: This was a single-center retrospective cohort study including hospitalized patients with TMA at a single center. We included all consecutive patients diagnosed with TMA between 2012 and 2021. TMA was defined based on the presence of anemia (hemoglobin level < 10 g/dL) and thrombocytopenia (platelet count < 150,000/µL), signs of hemolysis, and organ damage. We classified patients in eight categories: infections; Malignant Hypertension; Transplant; Malignancy; Pregnancy; Thrombotic Thrombocytopenic Purpura (TTP); Shiga toxin-mediated hemolytic uremic syndrome (STEC-SHU) and Complement Mediated TMA (aHUS). We fitted a model to classify patients using clinical characteristics, biochemical exams, and mean arterial pressure at presentation.

Results: We retrospectively retrieved TMA phenotypes using automatic strategies in electronic health records in almost 10 years (n = 2407). Secondary TMA was found in 97.5% of the patients. Primary TMA was found in 2.47% of the patients (TTP and aHUS). The best model was LightGBM with accuracy of 0.979, and multiclass ROC-AUC of 0.966. The predictions had higher accuracy in most TMA classes, although the confidence was lower in aHUS and STEC-HUS cases.

Conclusion: Secondary conditions were the most common etiologies of TMA. We retrieved comorbidities, associated conditions, and mean arterial pressure to fit a model to predict TMA and define TMA phenotypic characteristics. This is the first multiclass model to predict TMA including primary and secondary conditions.

Citing Articles

Recommendations for diagnosis and treatment of Atypical Hemolytic Uremic Syndrome (aHUS): an expert consensus statement from the Rare Diseases Committee of the Brazilian Society of Nephrology (COMDORA-SBN).

Vaisbich M, Modelli de Andrade L, Barbosa M, Castro M, Miranda S, Poli-de-Figueiredo C J Bras Nefrol. 2025; 47(2):e20240087.

PMID: 39918340 PMC: 11804885. DOI: 10.1590/2175-8239-JBN-2024-0087en.

References
1.
Inker L, Astor B, Fox C, Isakova T, Lash J, Peralta C . KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014; 63(5):713-35. DOI: 10.1053/j.ajkd.2014.01.416. View

2.
Franchini M . Atypical hemolytic uremic syndrome: from diagnosis to treatment. Clin Chem Lab Med. 2015; 53(11):1679-88. DOI: 10.1515/cclm-2015-0024. View

3.
Yoon J, Lee S, Sun C, Kim D, Kim I, Yoon S . MED-TMA: A clinical decision support tool for differential diagnosis of TMA with enhanced accuracy using an ensemble method. Thromb Res. 2020; 193:154-159. DOI: 10.1016/j.thromres.2020.06.045. View

4.
Bendapudi P, Hurwitz S, Fry A, Marques M, Waldo S, Li A . Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017; 4(4):e157-e164. DOI: 10.1016/S2352-3026(17)30026-1. View

5.
Vaisbich M, Modelli de Andrade L, de Menezes Neves P, Palma L, Castro M, Silva C . Baseline characteristics and evolution of Brazilian patients with atypical hemolytic uremic syndrome: first report of the Brazilian aHUS Registry. Clin Kidney J. 2022; 15(8):1601-1611. PMC: 9308094. DOI: 10.1093/ckj/sfac097. View